Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.1, Iss.2, 2005-08, pp. : 295-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer Bivalacqua Trinity J Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review

Current Drug Abuse Reviews, Vol. 4, Iss. 2, 2011-06 ,pp. : 87-94

Bentham Science Publishers

Access to resources Recommend Favorite

FR226807: a potent and selective phosphodiesterase type 5 inhibitor

By Hosogai N. Hamada K. Tomita M. Nagashima A. Takahashi T. Sekizawa T. Mizutani T. Urano Y. Kuroda A. Sawada K. Ozaki T. Seki J. Goto T.

European Journal of Pharmacology, Vol. 428, Iss. 2, 2001-10 ,pp. : 295-302

Elsevier

Access to resources Recommend Favorite

Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859

By Qiu Y. Bhattacharjee S. Kraft P. John T.M. Craig E. Haynes-Johnson D. Guan J. Jiang W. Macielag M. Sui Z. Clancy J. Lundeen S.

European Journal of Pharmacology, Vol. 472, Iss. 1, 2003-07 ,pp. : 73-80

Elsevier

Access to resources Recommend Favorite

Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor

By Mochida H. Takagi M. Inoue H. Noto T. Yano K. Fujishige K. Sasaki T. Yuasa K. Kotera J. Omori K. Kikkawa K.

European Journal of Pharmacology, Vol. 456, Iss. 1, 2002-12 ,pp. : 91-98

Elsevier

Access to resources Recommend Favorite